Search Results

You are looking at 1 - 10 of 198 items for :

  • "new drugs" x
Clear All
Full access

Andrew Wagner

advanced soft tissue sarcomas . Invest New Drugs 2000 ; 18 : 253 – 259 . 10. Luce JK Thurman WG Isaacs BL Talley RW . Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388) . Cancer Chemother

Full access

Alessandra Larocca and Antonio Palumbo

. Long-term results of autologous and allogeneic transplantation, before the addition of new drugs, show that several patients experience prolonged PFS, and a small proportion of them can achieve cure. Two trials compared the efficacy of single versus

Full access

Andy I. Chen and Ranjana H. Advani

Edited by Kerrin G. Robinson

Peripheral T-cell lymphomas (PTCLs) are a rare and diverse group of neoplasms with a poor prognosis. Management of these disorders has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with PTCL. Given the rarity of PTCL, much of the literature consists of studies with small sample size and anecdotal case reports. Therefore, no consensus exists on the best therapeutic strategy for either newly diagnosed or relapsed/refractory PTCL. This article reviews promising novel approaches in the treatment of PTCL and its subtypes. Investigation into the pathogenesis of PTCL has also identified new targets for treatment. These emerging therapies include new uses of existing agents and the development of novel agents specifically targeted against T-cell lymphoma. Results using antimetabolites, immunotherapies, and histone deacetylase inhibitors have been particularly encouraging. These novel therapies are being tested as single agents and in combination with conventional lymphoma regimens in the frontline and salvage settings. Because of the rarity and heterogeneity of PTCL, national and international cooperation is needed to conduct the clinical studies required for the development of more effective treatment paradigms. These efforts are ongoing and will hopefully guide new strategies to improve the historically poor outcome of PTCL.

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead and Rashmi Kumar

considering continuing up to 10 years of tamoxifen therapy (see BINV-J; page 441). First-Line Endocrine Therapy for Metastatic Hormone Receptor–Positive Breast Cancer Editor's Note: Updates on new drug approvals, not available at press time, can be

Full access

Erica L. Mayer, Nancy U. Lin and Harold J. Burstein

of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects . Invest New Drugs 2005 ; 23 : 39 – 49 . 48. Versola MJ Burris HA III Jones S . Clinical activity of GW572016 in EGF10003 in patients with solid tumors [abstract] . J

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson and Paul G. Richardson

. A new severe adverse effect of a new drug . Am J Hematol 2007 ; 82 : 502 – 503 . 69 Mitsiades N Mitsiades CS Poulaki V . Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic

Full access

Stephen Harnicar

patients, adverse effects, presence of mutations in the BCR-ABL kinase domain, and cost should be considered. Once chosen, drug interactions should be evaluated for all patients. New drugs are being studied to prevent disease progression and for patients

Full access

Florian Muller, Yu-Hsi Lin, Nikunj Satani and Naima Hammoudi

phosphorylation (OxPhos), including a new drug developed at MD Anderson Cancer Center by the Institute of Applied Cancer Science (IACS), which inhibits OxPhos by binding mitochondrial complex I with nM affinity. Exquisite sensitivity to OxPhos inhibition derives

Full access

Metastatic Colon Cancer, Version 3.2013

Featured Updates to the NCCN Guidelines

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory and Deborah A. Freedman-Cass

, the type and timing of prior therapy, the differing toxicity profiles of the constituent drugs, and the KRAS status of the tumor. This year, the panel discussed data pertaining to new drugs and other changes to the continuum of systemic therapy for

Full access

time to treat head and neck cancer patients, and pralatrexate was designed to be a new drug that works better. Laboratory studies have shown that pralatrexate works better than methotrexate at killing cancer cells. Pralatrexate has already been